162 related articles for article (PubMed ID: 32683606)
21. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
[TBL] [Abstract][Full Text] [Related]
24. U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer.
Singh H; Walker AJ; Amiri-Kordestani L; Cheng J; Tang S; Balcazar P; Barnett-Ringgold K; Palmby TR; Cao X; Zheng N; Liu Q; Yu J; Pierce WF; Daniels SR; Sridhara R; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Aug; 24(15):3486-3491. PubMed ID: 29523624
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials.
Tao Z; Li SX; Shen K; Zhao Y; Zeng H; Ma X
Clin Drug Investig; 2019 Jan; 39(1):27-43. PubMed ID: 30370488
[TBL] [Abstract][Full Text] [Related]
26. Neratinib (Nerlynx) for HER2-positive breast cancer.
Med Lett Drugs Ther; 2018 Jan; 60(1539):23. PubMed ID: 29364199
[No Abstract] [Full Text] [Related]
27. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Chan A; Ruiz-Borrego M; Marx G; Chien AJ; Rugo HS; Brufsky A; Thirlwell M; Trudeau M; Bose R; García-Sáenz JA; Egle D; Pistilli B; Wassermann J; Cheong KA; Schnappauf B; Semsek D; Singer CF; Foruzan N; DiPrimeo D; McCulloch L; Hurvitz SA; Barcenas CH
Breast; 2023 Feb; 67():94-101. PubMed ID: 36702070
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
Awada A; Dirix L; Manso Sanchez L; Xu B; Luu T; Diéras V; Hershman DL; Agrapart V; Ananthakrishnan R; Staroslawska E
Ann Oncol; 2013 Jan; 24(1):109-16. PubMed ID: 22967996
[TBL] [Abstract][Full Text] [Related]
29. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
Freedman RA; Gelman RS; Agar NYR; Santagata S; Randall EC; Gimenez-Cassina Lopez B; Connolly RM; Dunn IF; Van Poznak CH; Anders CK; Melisko ME; Silvestri K; Cotter CM; Componeschi KP; Marte JM; Moy B; Blackwell KL; Puhalla SL; Ibrahim N; Moynihan TJ; Nangia J; Tung N; Burns R; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU;
Clin Breast Cancer; 2020 Apr; 20(2):145-151.e2. PubMed ID: 31558424
[TBL] [Abstract][Full Text] [Related]
30. Adverse cutaneous effects of neratinib.
Hamid RN; Ahn CS; Huang WW
J Dermatolog Treat; 2019 Aug; 30(5):487-488. PubMed ID: 30321080
[TBL] [Abstract][Full Text] [Related]
31. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
[TBL] [Abstract][Full Text] [Related]
32. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis.
Nasrazadani A; Brufsky A
Future Oncol; 2020 Mar; 16(7):247-254. PubMed ID: 32057254
[TBL] [Abstract][Full Text] [Related]
33. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
34. Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.
Oliveira M; Garrigós L; Assaf JD; Escrivá-de-Romaní S; Saura C
Expert Rev Anticancer Ther; 2020 Sep; 20(9):731-741. PubMed ID: 32862744
[TBL] [Abstract][Full Text] [Related]
35. Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
Jackisch C; Barcenas CH; Bartsch R; Palma JD; Glück S; Harbeck N; Macedo G; O'Shaughnessy J; Pistilli B; Ruiz-Borrego M; Rugo HS
Clin Breast Cancer; 2021 Oct; 21(5):e575-e583. PubMed ID: 33678567
[TBL] [Abstract][Full Text] [Related]
36. Neratinib for the treatment of HER2-positive early stage breast cancer.
Echavarria I; López-Tarruella S; Márquez-Rodas I; Jerez Y; Martin M
Expert Rev Anticancer Ther; 2017 Aug; 17(8):669-679. PubMed ID: 28649882
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
Abraham J; Montero AJ; Jankowitz RC; Salkeni MA; Beumer JH; Kiesel BF; Piette F; Adamson LM; Nagy RJ; Lanman RB; Sperinde J; Huang W; Allegra CJ; Srinivasan A; Wang Y; Pogue-Geile KL; Lucas PC; Jacobs SA
J Clin Oncol; 2019 Oct; 37(29):2601-2609. PubMed ID: 31442103
[TBL] [Abstract][Full Text] [Related]
38. Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics.
Lai J; Zhuo X; Yin K; Jiang F; Liu L; Xu X; Liu H; Wang J; Zhao J; Xu W; Yang S; Guo H; Yuan X; Lin X; Qi F; Fu G
Anticancer Drugs; 2023 Jul; 34(6):747-762. PubMed ID: 36378136
[TBL] [Abstract][Full Text] [Related]
39. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.
Guy M; Teixeira A; Shrier A; Meschter C; Bolognese J; Chaturvedi P
PLoS One; 2024; 19(1):e0282769. PubMed ID: 38265977
[TBL] [Abstract][Full Text] [Related]
40. Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.
Jerez Y; Herrero B; Arregui M; Morón B; Martín M; Echavarría I
Future Oncol; 2020 Jun; 16(17):1165-1177. PubMed ID: 32458702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
